Leveraging ctDNA to Detect Minimal Residual Disease Following Surgery
Kara Nyberg, PhDCurative therapy remains elusive in early-stage NSCLC following surgical resection, sometimes even for patients with stage I disease. Adjuvant therapy can be of benefit, but only for a select few. As shown in the Lung Adjuvant […] Read more
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy
Kara Nyberg, PhDTargeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […] Read more
Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy
Joy CurzioIn his keynote address during the IASLC 2020 Hot Topic Meeting: Liquid Biopsy, co-chair Christian Rolfo, MD, PhD, MBA, provided an overview of the fastpaced evolution of liquid biopsy. In 2018, at the time of […] Read more
FDA Perspectives on the Use of Liquid Biopsy in NSCLC
Kara Nyberg, PhDThe US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of […] Read more
Biopsy Options Create New Decision-making Points for Clinicians
Kara Nyberg, PhDUnderstanding the differences in liquid biopsy approaches, as well as how they complement tissue, can be important to therapeutic selection and outcomes. Read more
The RAMES Study: A New Strategy of Targeting Angiogenesis in Mesothelioma
Federica Grosso, MD+more
At this year’s American Society of Clinical Oncology Virtual Meeting, the final results of the RAMES study were presented.1 RAMES was a prospective, placebo-controlled, phase II, randomized study in which […] Read more
Elimination of Clinical Trial Disparities Requires a New Lens for Viewing Justice, New Approach to Patient’s Role
By Joy Curzio Although there has been tremendous progress in lung cancer over the past 10 years, with a number of new drug indications being approved in the United States […] Read more
Immunotherapy, TKIs for Resectable/Resected NSCLC: Dr. Masahiro Tsuboi Provides a Comprehensive Overview of Promising Phase II Data, Phase III Status
By Jill Daigneault, PhD Surgical outcomes for early-stage NSCLC are still very poor due to the high rate of recurrence through distant metastases. It is likely that these distant metastases […] Read more
First-line Sintilimab Plus Platinum-Based Chemotherapy Prolongs PFS in Advanced Nonsquamous NSCLC
By Kara Nyberg, PhD Adding sintilimab, an anti-PD-1 antibody, to first-line platinum-based chemotherapy enhances efficacy in patients with locally advanced or metastatic nonsquamous NSCLC. In the randomized, placebo-controlled, phase III […] Read more
Register Now REGISTER NOW for the Medscape Education and IASLC Exclusive Webinar: Immunotherapy and the COVID-19 Pandemic: Addressing Clinical Case Challenges in Lung Cancer on Tuesday, August 11, 2020 @ […] Read more